Antiproliferative effect of the tripeptide pyroGlu-Phe-GlyNH2 on murine melanocytes: Transitory delay of cell growth in vitro and the cell cycle specificity

Experimental Cell Research

Volumn 243, Issue 2, 1998, Pages 367-374

  Gembitsky, Dmitry S ^a   Reichelt, Karl L ^a   Elgjo, Kjell ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Cell cycle; Cell proliferation; Growth inhibitors; Melanocytes; Mitosis; Oligopeptides

Indexed keywords

TRIPEPTIDE;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; GROWTH INHIBITION; MELANOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; MURINAE;

EID: 0032531215     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1998.4164     Document Type: Article

References (46)

1. Slominski A., Paus R. Melanogenesis is coupled to murine anagen: Toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J. Invest. Dermatol. 101:1992;90S-97S.
2. Abdel-Malek Z. A., Swope V. B., Nordlund J. J. The nature and biological effects of factors responsible for proliferation and differentiation of melanocytes. Pigment Cell Res. Suppl 2:1992;43-47.
3. Hirobe T. Control of melanocyte proliferation and differentiation in the mouse epidermis. Pigment Cell Res. 5:1992;1-11.
4. Hunt G. Melanocyte-stimulating hormone: A regulator of human melanocyte physiology. Pathobiology. 63:1995;12-21.
5. Swope V. B., Medrano E. E., Smalara D., Abdel-Malek Z. A. Long-term proliferation of human melanocytes is supported by the physiologic mitogens α-melanotropin, endothelin-1, and basic fibroblast growth factor. Exp. Cell Res. 217:1995;453-459.
6. Bordoni R., Fine R., Murray D., Richmond A. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes. J. Cell. Biochem. 44:1990;207-219.
7. Shih I. M., Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo. 8:1994;113-123.
8. Rodeck U., Bossler A., Graeven U., Fox F. E., Nowell P. C., Knabbe C., Kari C. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 54:1994;575-581.
9. Baserga R. The insulin-like growth factor I receptor: a key to tumor growth. Cancer Res. 55:1995;249-252.
10. Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type I insulin-like growth factor receptor. Cancer Res. 54:1994;4848-4850.
11. Swope V. B., Abdel-Malek Z. A., Kassem L. M., Nordlund J. J. Interleukins 1α and 6 and tumor necrosis factor-α are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J. Invest. Dermatol. 96:1991;180-185.
12. Krasagakis K., Garbe C., Eberle T., Orfanos C. E. Tumor necrosis factor and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro. Arch. Dermatol. Res. 287:1995;259-265.
13. Garbe C., Krasagakis K., Zouboulis C. C., Schroder K., Kruger S., Stadler R., Orfanos C. E. Antitumor activities of interferon alpha, beta and gamma and their combinations on human melanoma cells in vitro: Changes of proliferation, melanin synthesis and immunophenotype. J. Invest. Dermatol. 95:1990;231S-237S.
14. Abdel-Malek Z. A., Swope V. B., Amornsiripanitch N., Nordlund J. J. In vitro modulation of proliferation and melanization of S91 melanoma cells by prostaglandins. Cancer Res. 47:1987;3141-3146.
15. DiSorbo D. M., McNulty B., Nathanson L. In vitro growth inhibition of human malignant melanoma cells by glucocorticoids. Cancer Res. 43:1983;2664-2667.
16. 3. J. Cell. Physiol. 136:1988;273-280.
17. Gembitsky D. S., Reichelt K. L., Haakonsen P., Paulsen J. E., Elgjo K. Identification of a melanocyte growth-inhibiting tripeptide and determination of its structure. J. Peptide Res. 51:1998;80-84.
18. Elgjo K. Pentapeptide growth inhibitors, carcinogenesis, and cancer. New Frontiers in Cancer Causation. 1993;Taylor & Francis, Washington. p. 125-137.
19. Paukovits W. R., Laerum O. D. Isolation and synthesis of a hemoregulatory peptide. Z Naturforsch. 37:1982;1297-1300.
20. Elgjo K., Reichelt K. L. Purification and characterization of a mitosis inhibiting epidermal peptide. Cell Biol. Int. Rep. 8:1984;379-382.
21. Paulsen J. E., Reichelt K. L., Petersen A. K. Purification and characterization of a growth inhibitory hepatic peptide. Virchows Arch. B Cell Pathol. 54:1987;152-154.
22. Skraastad Ø., Fossli T., Edminson P. D., Reichelt K. L. Purification and characterization of a mitosis inhibitory tripeptide from mouse intestinal extracts. Epithelia. 1:1987;107-119.
23. Lenfant M., Wdzieczak-Bakala J., Guittet E., Prome J. C., Sotty D., Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc. Natl. Acad. Sci. USA. 86:1989;779-782.
24. Gembitsky D. S., Popova N. Y., Antokhin A. I., Podusov Y. N., Karpets L. Z., Adrianov N. V., Romanov Y. A. The Ehrlich ascites carcinoma (EAC) contains 300-500 Da inhibitor(s) suppressing DNA synthesis in cultured EAC cells and EAC cell division in tumor-bearing mice. Oncol. Rep. 3:1996;333-338.
25. Gembitsky D. S., Antokhin A. I., Popova N. Y., Podusov Y. N., Romanov Y. A. Comparative analysis of radiometric and autoradiographic methods in the investigation of DNA synthetic activity of tumor cellsin vitro. Oncol. Rep. 4:1997;1301-1304.
26. Elgjo K., Reichelt K. L., Gembitsky D. S. Growth-inhibiting N-substituted endogenous peptides. Progress in Molecular and Subcellular Biology: Inhibitors of Cell Growth. 1998;Springer Verlag, Berlin, Heidelberg, New York.
27. Marshall E., Lord B. I. Feedback inhibitors in normal and tumor tissues. Int. Rev. Cytol. 167:1996;185-261.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
29. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival: Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods. 89:1986;271-277.
30. LaBella F. S., Geiger J. D., Glavin G. B. Administered peptides inhibit the degradation of endogenous peptides: The dilemma of distinguishing direct from indirect effect. Peptides. 6:1985;645-660.
31. Skraastad Ø., Reichelt K. L. Further studies on the biological characteristics of an endogenous colon mitosis inhibitor: Comparison with some structurally related peptides. Virchows Arch. B Cell Pathol. 56:1989;321-325.
32. Elgjo K., Reichelt K. L. Mouse epidermal cell renewal after topical treatment with different concentrations of the epidermal peptide pyroGlu-Glu-Asp-Ser-GlyOH. Virchows Arch. B Cell Pathol. 59:1990;89-93.
33. Paulsen J. E., Sundby-Hall K., Endresen L., Rugstad H. E., Reichelt K. L., Elgjo K. The peptide pyroGlu-Gln-Gly-Ser-Asn, isolated from mouse liver, inhibits growth of rat hepatoma cells in vitro. Carcinogenesis. 12:1991;207-210.
34. Paus R., Stenn K. S., Elgjo K. The epidermal pentapeptide pyroGlu-Glu-Asp-Ser-GlyOH inhibits murine hair growth in vivo and in vitro. Dermatologica. 183:1991;172-178.
35. Iversen O. H., Elgjo K., Paulsen J. E., Reichelt K. L. Moderate enhancement of the promotion phase of skin tumorigenesis in hairless mice by topical pretreatment with a mitosis-inhibiting epidermal pentapeptide. Carcinogenesis. 14:1993;2537-2542.
36. Guigon M., Bonnet D. Inhibitory peptides in hematopoiesis. Exp. Hematol. 23:1995;477-481.
37. Jackson J. D., Yan Y., Ewel C., Talmadge J. E. Activity of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures. Exp. Hematol. 24:1996;475-481.
38. Volkov L., Quere P., Goudert F., Comte L., Praloran V. The tetrapeptide AcSDKP, a physiological inhibitor of normal cell proliferation, reduces the S phase entry of continuous cell lines. Exp. Cell Res. 223:1996;112-116.
39. Volkov L., Quere P., Goudert F., Comte L., Antipov Y., Praloran V. The tetrapeptide AcSDKP, a negative regulator of cell cycle entry, inhibits the proliferation of human and chicken lymphocytes. Cell. Immunol. 168:1996;302-306.
40. Elgjo K., Reichelt K. L., Hennings H., Michael D., Yuspa S. H. Purified epidermal pentapeptide inhibits proliferation and enhances terminal differentiation in cultured mouse epidermal cells. J. Invest. Dermatol. 87:1986;555-558.
41. Jensen P. K., Elgjo K., Laerum O. D., Bolund L. Synthetic epidermal pentapeptide and related growth inhibitory peptides inhibit proliferation and enhance differentiation in primary and regenerating cultures of human epidermal keratinocytes. J. Cell Sci. 97:1990;51-58.
42. Laerum O. D., Paukovits W. R. Modification of mouse hemopoietic cell proliferation in vivo by a hemoregulatory pentapeptide (HP5b): Relation to circadian rhythms. Virchows Arch. B Cell Pathol. 46:1984;333-348.
43. Bramucci M., Miamo A., Amici D. Epidermal inhibitory pentapeptide phosphorylated in vitro by calf thymus protein kinase N II is protected from serum enzyme hydrolysis. Biochem. Biophys. Res. Commun. 183:1992;474-480.
44. 2+. FEBS Lett. 291:1991;67-70.
45. Angiolillo A., Bramucci M., Marsili V., Panara F., Miano A., Amici D., Gianfranceschi G. L. Phosphorylation of synthetic acidic peptides by casein kinase II: Evidence for competition with phosphorylation of proteins involved in transcription. Mol. Cell. Biochem. 125:1993;65-72.
46. iα. FEBS Lett. 269:1990;11-14.